
[GRAILâ€™s](https://grail.com/press-releases/grail-announces-significant-progress-with-multi-cancer-early-detection-test-including-fda-breakthrough-device-designation/)cell-free DNA methylation assay for early pan-cancer diagnosis were approved in May 13, 2019. Memorial Sloan Kettering Cancer Center received approval on June 11 2019, for their new molecular assay called Analysis of Circulating cfDNA to Evaluate Somatic Status ([MSK-ACCESS](https://www.genomeweb.com/liquid-biopsy/memorial-sloan-kettering-nears-approval-liquid-biopsy-test-describes-validation-aacr)). 
